-
ARTES and Basic Pharma near completion of their joint rHSA project
ARTES Biotechnology and Basic Pharma are almost there! The companies are nearing completion of their joint project with the production of recombinant Human Serum Albumin (rHSA) and the first vials are expected to be available this summer. ARTES, a leading company that specialized in developing and transferring recombinant cell lines and protein production processes from microbial expression systems, and Basic Pharma, a pharmaceutical company focusing on pharmaceutical products, are delighted to announce significant progress in their strategic collaboration to produce recombinant Human Serum Albumin derived from Hansenula yeast. The teams have been working successfully on the development of rHSA and the project is on track to completion. The releasing of…
-
ARTES Biotechnology announce expansion of the management board
ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Director beginning of the year. He will manage the company in close cooperation with Dr. Michael Piontek, Managing Director and founder of ARTES Biotechnology and with Dr. Melanie Piontek, Business Development Director. Volker Jenzelewski started his career at Rhein Biotech GmbH in 1993 after graduating in biology. In positions of increasing responsibility in technical management and GMP manufacturing, Mr. Jenzelewski eventually became Director of Process Development and Head of Manufacturing at Dynavax Europe. His final responsibility was the validation of antigen production and the support of regulatory filings for HEPLISAV-B®, the lead product of…
-
ARTES Biotechnology and Basic Pharma join in a strategic Collaboration and Co-Marketing Partnership for Pharmaceutical Recombinant Protein Production
company focusing on niche pharmaceutical products, are proud to announce a strategic collaboration aimed at advancing pharmaceutical innovation. Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies for the development and production of nonGMP recombinant proteins in a first step. This initial phase will pave the way for subsequent upgrades to meet Good Manufacturing Practice (GMP) pharmaceutical standards. The overarching objective of this alliance is to establish a streamlined supply chain process that expedites time-to-market for new pharmaceutical products. The inaugural product to emerge from this collaboration is Human Serum Albumin (HSA), derived from the Hansenula polymorpha…
-
ARTES 20th Year Anniversary – a short overview
In 2002 at May 10th Michael Piontek founded ARTES as a one-man operation executing and taking care of two license deals as part of a severance agreement. He was absolute sure that this will be an interim solution only while looking for new job opportunities. Nevertheless, as always, things took an unexpected course. About half a year later ARTES has grown, first colleagues joined and the first company rooms were contracted. In 2007 ARTES and its team were in need for more room capacity, especially regarding laboratories. Therefore, we moved to our nowadays known facility at Elisabeth-Selbert-Str.9 in Langenfeld, Germany. From this site, ARTES today operates worldwide from 850 sqm…
-
Cellumed and ARTES Sign Development and License Agreement
Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines. Under this agreement, ARTES shall be responsible for the development of high yield microbial cell lines expressing two recombinant enzymes. Further steps at ARTES will include the development of up- and downstream processes as well as of the analytical assays to characterize the two products. Results will be transferred by ARTES to its German CMO partner Richter-Helm BioLogics GmbH &…
